MarginsXMarginsX
Home › Markets › Health Care › WVE

Wave Life Sciences Inc. (WVE)

WVE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$2.87
-8.31% on the day
Market cap
$566.0M
Small cap
Revenue · 2025
$42.7M
-60.5% on 2024
Net income · 2025
-$204.4M
-478.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1631574/000119312526073472/0001193125-26-073472-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerWVE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySingapore
IPO year2015
SEC CIK0001631574
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$42.7M
Net income-$204.4M
Operating income-$215.4M
Net margin-478.3%
Operating margin-504.1%
Revenue growth-60.5%
Cash$602.1M
Total assets$638.5M
P/E (computed)Net income was not positive
P/S (computed)13.2×

Warning signs

Cash runway
11.4 months
$197.3M cash at September 30, 2026
Share count, 1 year
+18.0%
2025-11-07 to 2026-10-21 · +99.1% over 3 years
Going-concern doubt
No
10-Q filed October 27, 2026
Insider net buying, 12 months
$66.6M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-27
Cash and burn$197.3M cash; operating cash flow -$51.8M a quarter.Report 2026-09-30
Shares outstanding197,228,968 (2026-10-21); 167,181,784 a year earlier; 99,053,902 three years earlier.Cover page 2026-10-21
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2025-12-11
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG LLP, Boston, Massachusetts, United StatesPCAOB Form AP 2026-03-24
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $82.6M, sold $15.9M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$13.2M-$61.9M-$60.1M$197.3MNo debt tags$70.9M10-Q 2026-10-27
Q2 2026
2026-06-30
$2.3M-$69.4M-$53.6M$368.0MNo debt tags$65.4M10-Q 2026-07-30
Q1 2026
2026-03-31
$38.2M-$26.1M-$59.6M$544.6MNo debt tags$71.8M10-Q 2026-04-28
Q4 2025
2025-12-31
$17.2M-$53.2M-$33.8M$602.1MNo debt tags$42.7M10-K 2026-02-26
Q3 2025
2025-09-30
$7.6M-$53.9M-$44.7M$196.2MNo debt tagsNeeds four quarters10-Q 2026-10-27
Q2 2025
2025-06-30
$8.7M-$50.5M-$46.0M$208.5MNo debt tagsNeeds four quarters10-Q 2026-07-30
Q1 2025
2025-03-31
$9.2M-$46.9M-$63.0M$243.1MNo debt tagsNeeds four quarters10-Q 2026-04-28
Q4 2024
2024-12-31
Not filed$29.3M-$43.6M$302.1MNo debt tags$108.3M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-08-10
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-10-27
Latest current report8-K2026-10-27
Latest proxyDEF 14A2026-10-14

Source: SEC EDGAR submissions feed, 744 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.1%
1 month-0.3%
3 months-39.8%
Year to date-81.6%
1 year-53.1%
From 52-week high-85.3%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
HELPHelus Pharma Inc.$7.67-13.53%$560.4M
ACRSAclaris Therapeutics Inc.$3.60-8.04%$571.8M
EVOEvotec SE$1.56-1.27%$555.0M
ZVRAZevra Therapeutics Inc.$9.25+1.87%$550.4M
CLYMClimb Bio Inc.$9.94-4.05%$583.9M
AVBPArriVent BioPharma Inc.$11.56-11.15%$597.9M
INDPIndaptus Therapeutics Inc.$3.45+8.83%$529.9M
GERNGeron Corporation$0.9419-2.60%$606.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier